Two-Step Approach for the Prediction of Future Type 2 Diabetes Risk

Muhammad A. Abdul-Ghani, MD, PhD
Tamam Abdul-Ghani, MSC
Michael P. Stern, MD
Jasmina Karavic, MD

Tina-Maja Tuomi, MD, PhD
Insoma Bo, MD
Ralph A. DeFronzo, MD
Leif Groop, MD

OBJECTIVE—To develop a model for the prediction of type 2 diabetes mellitus (T2DM) risk on the basis of a multivariate logistic model and 1-h plasma glucose concentration (1-h PG).

RESEARCH DESIGN AND METHODS—The model was developed in a cohort of 1,562 nondiabetic subjects from the San Antonio Heart Study (SAHS) and validated in 2,395 nondiabetic subjects in the Botnia Study. A risk score on the basis of anthropometric parameters, plasma glucose and lipid profile, and blood pressure was computed for each subject. Subjects with a risk score above a certain cut point were considered to represent high-risk individuals, and their 1-h PG concentration during the oral glucose tolerance test was used to further refine their future T2DM risk.

RESULTS—We used the San Antonio Diabetes Prediction Model (SADPM) to generate the initial risk score. A risk-score value of 0.065 was found to be an optimal cut point for initial screening and selection of high-risk individuals. A 1-h PG concentration >140 mg/dL in high-risk individuals (whose risk score was >0.065) was the optimal cut point for identification of subjects at increased risk. The two cut points had 77.8, 77.4, and 44.8% (for the SAHS) and 75.8, 71.6, and 11.9% (for the Botnia Study) sensitivity, specificity, and positive predictive value, respectively, in the SAHS and Botnia Study.

CONCLUSIONS—A two-step model, based on the combination of the SADPM and 1-h PG, is a useful tool for the identification of high-risk Mexican-American and Caucasian individuals.

Diabetes Care 34:2108–2112, 2011

The prevalence of type 2 diabetes mellitus (T2DM) has increased in recent decades to epidemic proportions (1). Because of the chronic course of T2DM, and the significant morbidity and mortality associated with the vascular complications of the disease, T2DM has become not only a serious public health threat but also a heavy economic burden on every health care system (2). Recent clinical trials have demonstrated that the incidence of T2DM can be reduced with lifestyle intervention (3,4) and pharmacotherapy (4,5) in subjects with impaired glucose tolerance (IGT). These results indicate that primary prevention of T2DM is a promising strategy to restrain the epidemic increase in disease prevalence and control the economic burden that it poses on health care expenditure.

Accurate identification of subjects at increased risk of future T2DM is essential for every prevention program. It minimizes the number of subjects in the intervention program and improves its efficacy and cost-effectiveness. All previous intervention trials that have tested the efficacy of various prevention strategies have recruited subjects with IGT (3–5) and/or impaired fasting glucose (IFG). Although subjects with IGT are at increased risk for future T2DM compared with individuals with normal glucose tolerance (NGT), only 35–50% of subjects with IGT convert to T2DM after 5–10 years (6–8), and, even after 20 years of follow-up, only ~50% of subjects with IGT convert to T2DM (8). Furthermore, ~30–40% of subjects who develop T2DM in prospective studies have NGT at baseline (7,8), suggesting that the future risk for T2DM is not similar among all subjects with IGT or NGT. Thus, by solely relying on IGT for the identification of subjects at increased T2DM risk, a large group of high-risk subjects with NGT remains unidentified (9).

These limitations associated with the use of IGT to identify high-risk individuals have lead to the development of prediction models based on multivariate logistic models using risk factors for T2DM (e.g., age, sex, BMI, fasting plasma glucose [FPG], lipid profile, and blood pressure) (10–18). These predictive models have been shown to perform as well as IGT in predicting future T2DM risk. Because all of the measurements required for these models are taken during the fasting state, these models have been advocated to replace IGT for the identification of subjects at increased risk for future T2DM without the need to perform an oral glucose tolerance test (OGTT).

Although multivariate prediction models have better sensitivity compared with IGT in identifying subjects at increased T2DM risk, they have relatively low specificity and positive predictive value (PPV). We previously (19–21) have shown that a plasma glucose concentration >155 mg/dL at 1 h during the OGTT identifies subjects at increased T2DM risk with relatively high sensitivity and specificity. We also demonstrated that the 1-h plasma glucose concentration (1-h PG) performs superiorly to both IGT and multivariate prediction models in the identification of high-risk individuals. Furthermore, we demonstrated that the addition of the 1-h PG to multivariate prediction models significantly improves their predictive power, indicating that the 1-h PG contains additional information about future T2DM risk compared with all known diabetes risk factors. However, similar to IGT, the 1-h PG requires a glucose load.

In this study, we used data from the San Antonio Heart Study (SAHS) to develop a two-step model for the prediction of future T2DM risk. This model involves screening all nondiabetic subjects using the
San Antonio Diabetes Prediction Model (SADPM) (14,19) and administering an oral glucose load to obtain the 1-h PG value, only in high-risk individuals, to further refine their future T2DM risk. We demonstrate that this two-step model decreases the number of subjects who require an oral glucose load and has high sensitivity, specificity, and PPV in identifying subjects at increased T2DM risk.

**RESEARCH DESIGN AND METHODS**—Subjects were participants of the SAHS (n = 1,562) (22) and the Botnia Study (n = 2,395) (23) who were free of diabetes at baseline. The two studies are prospective longitudinal studies in which nondiabetic subjects (Caucasians and Mexican Americans in the SAHS and Caucasians in the Botnia Study) were recruited and followed for 7–8 years. Detailed descriptions of the Botnia Study and SAHS previously have been published (22,23). Only subjects with 2-h plasma glucose concentrations (2-h PG) <200 mg/dL and FPG <125 mg/dL at baseline were included in this study. Table 1 presents the baseline patient characteristics. All subjects completed a 7- to 8-year follow-up examination and had their diabetes outcome determined with a repeat OGTT.

**Study design**

During the baseline studies, clinical and anthropometric parameters (age, sex, BMI, and ethnicity) were collected. Blood pressure and plasma lipid concentrations were measured. In addition, all subjects received a 75-g OGTT following a 12-h overnight fast. Plasma glucose and serum insulin concentrations were measured at 0, 30, 60, and 120 min. After 7–8 years of follow-up, a repeat OGTT was performed and the diagnosis of diabetes was made on the basis of American Diabetes Association criteria (24) (2-h plasma glucose concentrations >200 mg/dL or FPG >126 mg/dL).

**Analytical methods**

Plasma glucose was measured at bedside with the glucose oxidase method using a Beckman Glucose Analyzer in both studies (Beckman Instruments, Fullerton, CA).

**Data analysis and statistical methods**

The two-step model is based on the concept of screening the population using the SADPM (14) and performing a 1-h PG only in high-risk individuals. The SADPM (14) is a multivariate logistic regression based on age, sex, BMI, ethnicity, FPG, HDL cholesterol, and blood pressure to compute a risk score for future T2DM. We used the dataset of the SAHS to develop the two-step model and the Botnia Study dataset to validate it.

In the first step, the SADPM, as published (14), was used to compute a score of T2DM risk for each participant. To obtain the optimal cut point above which subjects were considered at high risk, we constructed a receiver-operating characteristic curve by plotting the sensitivity against the false-positive rate, and the score value with the maximal sum of sensitivity and specificity was chosen to represent the optimal cut point. Likewise, the optimal cut point for the 1-h PG was determined by constructing a receiver-operating characteristic curve and defining the 1-h PG value with the maximal sum of sensitivity and specificity.

The predictive power of the two cut points (0.065 for the SADPM and 1-h PG >140 mg/dL, respectively) was tested in the Botnia Study dataset. The predictive power of the model was assessed by computing the sensitivity, specificity, and PPV in the Botnia Study and SAHS, and the result was compared with other prediction models.

Variables are presented as means ± SD. The significance of the mean differences was tested using ANOVA. Differences between categorical variables were tested using the χ² test. Statistical significance was considered at the level of P < 0.05. Statistical analysis was performed using the SPSS software package version 17.

**RESULTS**

**Model development**

Nondiabetic subjects in the SAHS who had their plasma glucose concentration measured at 0, 30, 60, and 120 min during the baseline OGTT and completed the 7–8 years of follow-up were used for model development. The cut point of the risk score that had the maximal sum of sensitivity and specificity was 0.065. A total of 739 of 1,562 (47%) study participants had a risk score below this value and were considered to be low-risk individuals. A total of 823 subjects (33%) had a risk score >0.065 and were considered to be at high risk. The optimal cut point of

| Table 1—Baseline characteristics of subjects who progressed to T2DM and nonprogressors in the SAHS and the Botnia Study |
|---------------------------------|-----------------|----------------|---------|
|                                | SAHS             | Botnia Study   |
|                                | Nonprogressors | Progressors | P       | Nonprogressors | Progressors | P       |
| n                              | 1,388           | 174           | <0.0001 | 2,271          | 124           | <0.0001 |
| Age (years)                    | 43 ± 1          | 48 ± 1        | <0.0001 | 46 ± 1         | 53 ± 1        | <0.0001 |
| Sex (% male)                   | 43.2            | 39%           |         | 45.9           | 43.2           |         |
| FPG (mg/dL)                    | 85 ± 1          | 95 ± 1        | <0.0001 | 89 ± 1         | 95 ± 1        | <0.0001 |
| 1-h PG (mg/dL)                 | 127 ± 1         | 179 ± 3       | <0.0001 | 124 ± 1        | 168 ± 3       | <0.0001 |
| 2-h PG (mg/dL)                 | 101 ± 1         | 137 ± 3       | <0.0001 | 99 ± 1         | 119 ± 3       | <0.0001 |
| HDL cholesterol (mg/dL)        | 48 ± 1          | 42 ± 1        | <0.0001 | 54.3 ± 1       | 49.5 ± 1      | <0.0001 |
| BMI (kg/m²)                    | 27.2 ± 0.2      | 31.2 ± 0.4    | <0.0001 | 25.6 ± 0.1     | 28.9 ± 0.4    | <0.0001 |
| Systolic blood pressure (mmHg) | 117 ± 1         | 124 ± 1       | <0.0001 | 129 ± 1        | 140 ± 2       | <0.0001 |
| Ethnicity (% white)            | 35               | 22             |         | 100             | 100             |         |
| 8-Year diabetes incidence rate (%) | 0                | 100             |         | 0                | 100             |         |
| SADPM risk score [median (range)] | 0.068 (0.001–0.94) | 0.28 (0.007–0.96) | <0.0001 | 0.185 (0.001–0.973) | 0.465 (0.013–0.959) | <0.0001 |

Data are means ± SEM, unless otherwise indicated. SADPM risk score refers to the median (range) risk score measured by the SADPM (according to ref. 14) at baseline.
1-h PG that had the maximal sum of sensitivity and specificity for the prediction of T2DM risk in the 823 subjects who had a risk score $>0.065$ was $140 \text{ mg/dL}$. Of 823 subjects with an elevated risk score, 452 subjects also had a 1-h PG $>140 \text{ mg/dL}$ and 371 subjects had a 1-h PG $<140 \text{ mg/dL}$. Thus, the 0.065 cut point for the risk score and 140 mg/dL for the 1-h PG had a sensitivity, specificity, and PPV of 77.8, 77.4, and 44.8%, respectively, for identifying subjects at increased future T2DM risk in the SAHS.

Table 2 demonstrates that subjects with a risk score $>0.065$ and 1-h PG $>140 \text{ mg/dL}$ had a 36-fold increase in their T2DM risk compared with subjects with a risk score $<0.065$ and 1-h PG $<140 \text{ mg/dL}$.

Model validation
Model validation was performed in the Botnia Study in 2,395 nondiabetic subjects who had their plasma glucose concentrations measured at 0, 30, 60, and 120 min during the baseline OGTT and completed a 7- to 8-year follow-up. A total of 419 of 2,395 (18%) subjects had a risk score $<0.065$ and, therefore, represent low-risk individuals. Of 1,976 subjects with a risk score $>0.065$, 734 had 1-h PG concentrations $>140 \text{ mg/dL}$ and represented the target population for intervention. The cut point of 0.065 for the SADPM and 140 mg/dL for the 1-h PG concentration had 76, 72, and 12% sensitivity, specificity, and PPV, respectively, in the Botnia Study.

Subjects with a risk score $>0.065$ and 1-h PG $>140 \text{ mg/dL}$ had a 25-fold increase in T2DM risk compared with subjects with a risk score $<0.065$ and 1-h PG $<140 \text{ mg/dL}$.

**CONCLUSIONS**—Accurate identification of subjects at increased future T2DM risk is pivotal to all intervention programs that aim to prevent and/or delay the onset on T2DM. Currently, two methods are available to identify subjects at increased risk of future T2DM: 1) 2-h 75-g OGTT to identify subjects with IGT (3–5) and 2) risk-score models computed with multivariate regression models based on diabetes risk factors (age, sex, BMI, FPG, lipid profile, and blood pressure) (10–18). Although the 2-h OGTT has been used in all previous clinical trials to identify high-risk subjects with IGT for intervention, it is inconvenient in routine clinical practice. Moreover, by solely relying on IGT to identify at-risk subjects, many subjects with NGT who are at increased risk of T2DM remain unidentified (9). On the other hand, risk-score models, such as the SADPM and other models, which require measurements taken only during the fasting state, are easy to use and also may identify high-risk individuals with NGT. It is important to note that all variables that were required to obtain the risk score by these prediction models are routinely collected in routine clinical practice and readily are available in the subject’s medical record. Thus, a risk score for future T2DM risk can be computed by the physician in the absence of the subject and without the need for an office visit. Despite the simplicity in using the risk-score models and their good sensitivity, they have several limitations. Performance of the risk score is weaker in populations other than that in which they were developed, and, as a result, the parameters of each model need to be reoptimized in each population. Another limitation of the risk-score model is that despite their good sensitivity in identifying high-risk individuals, they have relatively low specificity (40–60%) and PPV compared with IGT (documented with OGTT). In the current study, the specificity and PPV of the SADPM was approximately one-half of that obtained with 1-h PG and the two-step model in both the Botnia Study and SAHS. Moreover, the PPV of the risk score in the population in which it was developed failed to exceed 10% (13–18). Moreover, it is likely that these multivariate regression models would have even lower specificity and PPV when used in populations other than the one in which they were developed. For example, in the current study, the sensitivity of the SADPM was 88.8 and 97.4% in the SAHS and Botnia Study, respectively. However, the specificity and PPV were 52 and 19%, respectively, in the SAHS and 18 and 6%, respectively, in the Botnia Study (Table 3). Thus, by relying on multivariate models to identify high-risk individuals for prevention programs, many false-positive cases would be identified as high-risk individuals and would be invited to participate in the intervention program. This would increase the cost of the intervention program and reduce its efficacy and cost-effectiveness. Thus, despite the simplicity, convenience, and relatively low cost of using risk-score models to identify high-risk individuals, the relatively low PPV of these models will reduce the overall cost-effectiveness of any prediction-prevention program, which relies on a risk-score model for diabetes prediction. The two-step prediction model presented in the current study provides a balance between both approaches and has several advantages: 1) Because the variables required to establish the risk score (BMI, blood pressure, FPG, and lipid profile) are collected in routine clinical practice, they readily are available in medical records. Thus, the initial risk score using the SADPM can be computed without the need for an office visit by the patient. 2) By refining the risk for future diabetes with the 1-h PG, the specificity and PPV of the model is significantly improved (Table 3). Because of the week specificity and PPV of the SADPM, $>50\%$ of subjects classified as high-risk individuals ($>0.065$) are false-positively identified, and these false-positive individuals can be excluded from intervention program with the 1-h PG. Furthermore, use of the 1-h PG reduces the time required to perform the glucose load by 50% compared with establishing the diagnosis of IGT. Because only subjects with increased risk score ($>0.065$) are required to perform the glucose load, an office visit is required only in a subgroup of the population to identify individuals who truly are at increased future T2DM risk. Thus, similar to IGT, this approach has the advantage of having high specificity and PPV compared with high-risk-score models, while avoiding some of the limitations of IGT (e.g., reducing the time required for OGTT and decreasing the number of subjects required to perform glucose load). 3) The improved specificity and PPV obtained with the 1-h PG leads

**Table 2—T2DM risk associated with increased SADPM score and 1-h PG**

| Group | SAHS | Botnia Study |
|-------|------|--------------|
|       | Odds ratio (95% CI) | $P$ | Odds ratio (95% CI) | $P$ |
| $<0.065$, 1-h PG $<140$ | 1 | 1 |
| $<0.065$, 1-h PG $>140$ | 7.10 (2.78–18.1) | $<0.0001$ | 4.22 (0.37–47.5) | 0.289 |
| $>0.065$, 1-h PG $<140$ | 4.64 (1.94–11.1) | $<0.0001$ | 3.69 (0.86–15.70) | 0.062 |
| $>0.065$, 1-h PG $>140$ | 36.53 (16.9–79.0) | $<0.0001$ | 25.27 (6.18–103.2) | $<0.0001$ |
to a smaller number of individuals who are targeted for the intervention program, and this would substantially reduce the cost and increase the efficacy and cost-effectiveness. Although obtaining 1-h PG concentrations will increase the cost of screening, we believe that the decrease in intervention costs after the improvement in specificity and PPV of the two-step approach will outweigh the cost of performing the glucose load, and using the two-step model to identify high-risk individuals for the prevention program decreases the overall cost-effectiveness of the prediction-prevention program. 4) We have validated the two-step prediction model in a completely independent dataset with a different ethnicity (Swedish Caucasians versus Mexican Americans), suggesting that this model has the potential to perform well in other ethnic groups. 5) In the current study, we favored the SADPM over other risk-score models for several reasons: 1) the SADPM has been validated in other populations and 2) studies that have compared the sensitivity and specificity of the SADPM compared with other risk scores have reported similar or greater sensitivity of the SADPM to other models (e.g., Framingham Study and Atherosclerosis Risk in Communities Study risk scores). Although the specificity and PPV of the SADPM was slightly lower in other populations compared with Mexican Americans, the addition of 1-h PG to the SADPM improved the specificity and PPV of the two-step model.

Although the two-step model provides a balanced approach for identifying subjects at increased future T2DM risk, it has some limitations. It requires the performance of glucose load in a subgroup of the population, which is inconvenient, expensive, and requires a special office visit compared with only relying on the FPG and HbA1c. However, the information generated with the two-step model may outweigh the additional cost and inconvenience associated with the performance of glucose load. Moreover, glucose load may not be required in very-high-risk individuals (e.g., HbA1c >6% and FPG >115 mg/dL). In the Botnia Study, this subgroup (FPG >115 mg/dL and HbA1c >6.0%) had a 32% risk of T2DM over an 8-year period. However, this cut point had very high sensitivity (8%). Of note, all subjects with FPG >115 mg/dL and HbA1c >6.0% had a score in the SADPM >0.065 and 1-h PG >140 mg/dL. One could argue that in such a very-high-risk group, a glucose load may not be necessary. Tools to ascertain the risk for future diabetes are valuable to the extent one believes that it is important to detect diabetes as soon as it exists. Although there are no trials to inform us as to the urgency to detect diabetes, it is clear that hyperglycemia is the principal cause of microvascular complications (25), so any test or algorithm that might help to reduce the time spent with undetected hyperglycemia should intuitively be of benefit. Future studies should address the value of early detection and, by implication, the value of sensitive and specific risk-assessment tools for future diabetes, such as the one described here.

The low incidence rate of T2DM in the Botnia Study compared with the SAHS (Table 1) most likely explains the low PPV of the present model in this population. Of note, the 1-h PG resulted in a twofold increase in PPV compared with the SADPM in both populations, suggesting that the contribution of the 1-h PG improves the accuracy of the prediction model and is independent of the incidence rate of T2DM. The decreased T2DM incidence and decreased specificity and PPV in the Botnia Study results in a larger number of subjects required to perform an OGTT (82 vs. 53% in the SAHS).

In summary, we have demonstrated that a two-step approach based on a multivariate logistic model and a 1-h PG concentration during an OGTT identifies subjects at increased risk of T2DM with high sensitivity, specificity, and PPV compared with risk-score models or IFG and/or IGT. Although this approach requires the measurement of 1-h PG, the glucose load only needs to be admitted to a subgroup of the population. This model could provide a useful tool for the identification of subjects at increased risk of T2DM in the community.

Acknowledgments—No potential conflicts of interest relevant to this article were reported. M.A.A.-G. and T.A.-G. performed the analysis and wrote the manuscript. M.P.S. reviewed the manuscript and contributed to generating data. J.K. prepared the dataset for analysis. T.T., I.B., and L.G. contributed to generating data. R.A.D. reviewed the manuscript.

References
1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414–1431
2. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care 2008;31:1–20
3. Tuomilehto J, Lindstrom J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350
4. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence
Two-step prediction model of T2DM risk

of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
5. Gerstein HC, Yusuf S, Bosch J, et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–1105
6. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007;78:305–312
7. Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diab Med 2002;19:708–723
8. Dankner R, Abdul-Ghani MA, Gerber Y, Chetrit A, Wainstein J, Raz I. Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev 2007;23:551–558
9. Abdul-Ghani MA, Williams K, Stern MP, DeFronzo RA. A risk of progression to type 2 diabetes upon the relationship between the post-load plasma glucose and fasting plasma glucose concentrations. Diabetes Care 2006;29:1613–1618
10. Mann DM, Bertoni AG, Shimbo D, et al. Comparative validity of 3 diabetes mellitus risk prediction scoring models in a multiethnic US cohort: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2010;171:980–988
11. Stern M, Williams K, Eddy D, Kahn R. Validation of prediction of diabetes by the Archimedes model and comparison with other predicting models. Diabetes Care 2008;31:1670–1671
12. McNeely MJ, Boyko EJ, Leonetti DL, Kahn SE, Fujimoto WY. Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans. Diabetes Care 2003;26:758–763
13. Eschwege E, Charles MA, Simon D, Thibult N, Balkau B, Paris Prospective Study. Reproducibility of the diagnosis of diabetes over a 30-month follow-up: the Paris Prospective Study. Diabetes Care 2001;24:1941–1944
14. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002;136:575–581
15. Aekplakorn W, Bunnag P, Woodward M, et al. A risk score for predicting incident diabetes in the Thai population. Diabetes Care 2006;29:1872–1877
16. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005;165:2644–2650
17. Kanaya AM, Wassel Fyr CL, de Rereniere N, et al. Predicting the development of diabetes in older adults: the derivation and validation of a prediction rule. Diabetes Care 2005;28:404–408
18. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003;26:725–731
19. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern MP. What is the best predictor of future type 2 diabetes? Diabetes Care 2007;30:1544–1548
20. Abdul-Ghani MA, Abdul-Ghani TA, Ali N, DeFronzo RA. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 2008;31:1650–1655
21. Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Group L. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care 2009;32:281–286
22. Stern MP, Rosenthal M, Haffner SM, Hazuda HP, Franco LJ. Sex difference in the effects of sociocultural status on diabetes and cardiovascular risk factors in Mexican Americans: the San Antonio Heart Study. Am J Epidemiol 1984;120:834–851
23. Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 1996;45:1585–1593
24. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197
25. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007;24:137–144